How To Use CPT Code 0122U

CPT 0122U describes a proprietary laboratory analysis (PLA) code for the microfluidic flow adhesion of whole blood to P-Selectin in patients with sickle cell disease. This article will cover the official description, procedure, qualifying circumstances, appropriate usage, documentation requirements, billing guidelines, historical information, and examples of CPT code 0122U.

1. What is CPT Code 0122U?

CPT 0122U is a proprietary laboratory analysis (PLA) code that specifically applies to the microfluidic flow adhesion of whole blood to P-Selectin. This test is performed to assess the effects of drugs in preventing cell adhesion in patients with sickle cell disease. It is a flow-based cell adhesion assay that analyzes the interaction between endothelial P-Selectins and their counter ligands using whole blood samples.

2. Official Description

The official description of CPT code 0122U is: ‘Flow adhesion of whole blood to P-Selectin (WB-PSEL) assay, microfluidic, for sickle cell disease.’

3. Procedure

1. The lab analyst performs microfluidic flow-based cell adhesion analysis of whole blood samples on P-Selectin.
2. The analysis is based on the multistep cell adhesion process controlled by endothelial P-Selectins and their counter ligands.
3. Whole blood is subjected to physiologic flow across an adhesive substrate of P-Selectin.
4. Pretreated isolated leukocytes are perfused through microfluidic channels coated with P-Selectin.
5. Time-lapse images are used to measure cell rolling/sliding along the channel surface.
6. Proprietary software enables the selection and representation of cell movements by speed and vector, generating a dynamic adhesion index (dAI) from mean velocity for rolling objects and cell flux.

4. Qualifying circumstances

CPT code 0122U is used for patients with sickle cell disease (SCD), a group of inherited red blood cell disorders. The test is ordered to assess the therapeutic effects of antiadhesion medications in patients with SCD and to prevent pain crises, organ damage, and early morbidity and mortality from vascular occlusion. The test is performed on whole blood samples and requires microfluidic flow adhesion analysis on P-Selectin.

5. When to use CPT code 0122U

CPT code 0122U should be used when analyzing the microfluidic flow adhesion of whole blood to P-Selectin in patients with sickle cell disease. It is specifically designed for this purpose and should not be used for any other tests or conditions.

6. Documentation requirements

To support a claim for CPT code 0122U, the following documentation is required:

• Indication of sickle cell disease in the patient
• Details of the microfluidic flow adhesion analysis performed on P-Selectin
• Date and time of the test
• Results of the analysis, including the dynamic adhesion index (dAI)
• Signature of the lab analyst performing the test

7. Billing guidelines

When billing for CPT code 0122U, ensure that the test is performed for sickle cell disease and that the documentation requirements are met. This code should not be reported with any other CPT codes. It is important to check with the appropriate payer regarding any additional requirements or coverage for specimen collection.

8. Historical information

CPT code 0122U was added to the Current Procedural Terminology system on October 1, 2019. There have been no updates or changes to the code since its addition.

9. Examples

1. A lab analyst performing microfluidic flow adhesion analysis of whole blood to P-Selectin for a patient with sickle cell disease.
2. An assessment of the effects of antiadhesion medications in preventing cell adhesion in a patient with sickle cell disease using the microfluidic flow adhesion assay.
3. Measurement of cell rolling and sliding along microfluidic channels coated with P-Selectin in a whole blood sample from a patient with sickle cell disease.
4. Generation of a dynamic adhesion index (dAI) from mean velocity for rolling objects and cell flux in a microfluidic flow adhesion analysis of whole blood to P-Selectin.
5. Analysis of the interaction between endothelial P-Selectins and their counter ligands using time-lapse images of microfluidic flow adhesion in patients with sickle cell disease.
6. Performance of the microfluidic flow adhesion assay on whole blood samples to assess the effects of drugs in preventing cell adhesion in sickle cell disease patients.
7. Selection and representation of cell movements by speed and vector in a microfluidic flow adhesion analysis of whole blood to P-Selectin for sickle cell disease patients.
8. Measurement of cell rolling/sliding along the channel surface in a microfluidic flow adhesion assay for sickle cell disease patients.
9. Generation of a dynamic adhesion index (dAI) from mean velocity for rolling objects and cell flux in a microfluidic flow adhesion analysis of whole blood to P-Selectin for patients with sickle cell disease.
10. Analysis of the multistep cell adhesion process controlled by endothelial P-Selectins and their counter ligands in a microfluidic flow adhesion assay for sickle cell disease patients.